Jazz Pharmaceuticals plc (JAZZ)

Market Cap	11.66B +60.3%
Revenue (ttm)	4.27B +4.9%
Net Income	-356.15M
EPS	-5.84
Shares Out	61.56M
PE Ratio	n/a
Forward PE	8.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,326,379
Open	195.07
Previous Close	196.83
Day's Range	188.30 - 198.00
52-Week Range	95.49 - 198.00
Beta	0.25
Analysts	Strong Buy
Price Target	211.25 (+11.55%)
Earnings Date	Feb 24, 2026

About JAZZ

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2007
• Employees: 2,890
• Stock Exchange: NASDAQ
• Ticker Symbol: JAZZ
• Website: https://www.jazzpharma.com

Analyst Summary

According to 16 analysts, the average rating for JAZZ stock is "Strong Buy." The 12-month stock price target is $211.25, which is an increase of 11.55% from the latest price.

Price Target

$211.25

(11.55% upside)

Analyst Consensus: Strong Buy